Bronchiolitis. Other acute lower respiratory infections
Conditions
Interventions
Intervention 1: First group: receive 5 ml hypertonic saline 3% and 0.15 mg/kg nebulized salbutamol. Intervention 2: Second group: receive 5 ml normal saline 0.9% and 0.15 mg/kg nebulized salbutamol. I
Treatment - Drugs
First group: receive 5 ml hypertonic saline 3% and 0.15 mg/kg nebulized salbutamol.
Second group: receive 5 ml normal saline 0.9% and 0.15 mg/kg nebulized salbutamol.
Third group: receive 10 ml normal saline 0.9% and 0.15 mg/kg nebulized salbutamol.
Sponsors
Vice chancellor for research,Zahedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Months to 2 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age less than 2 year old; history of recent upper respiratory viral infection which caused wheeze and crackle in auscultation; CBSS 4-8 in admit. Exclusion criteria: age less than 1 month or more than 2 years old; history of recurrent attack of wheeze; sever neurological disorder; consolidation in Chest x ray; immune deficiency; congenital heart disease; history of premature (gestational age less than 34 weeks); birth weight less than 2500 gr; saturation of oxygen less than 85% in room; CBSS less than 4 or more than 8; unstable hemodynamic (heart rate more than 200 per minute, blood pressure 2 standard deviation more or less than normal range for age and sex, respiratory rate more than 70 per minute).
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory rate. Timepoint: Pretreatment and each 30 minute up to 3 times after the begining of treatment. Method of measurement: Counting respiratory rate in 1 minute.;O2 saturation. Timepoint: Pretreatment and each 30 minute up to 3 times after the begining of treatment. Method of measurement: Pulse oximetery.;Heart rate. Timepoint: Pretreatment and each 30 minute up to 3 times after the begining of treatment. Method of measurement: Counting heart rate in 1 minute.;Intercostal retraction. Timepoint: Pretreatment and each 30 minute up to 3 times after the begining of treatment. Method of measurement: Physical exam and score of CBSS (0,1,2,3).;Dyspnea. Timepoint: Pretreatment and each 30 minute up to 3 times after the begining of treatment. Method of measurement: Physical exam and score of CBSS (0,1,2,3).;Wheezing. Timepoint: Pretreatment and each 30 minute up to 3 times after the begining of treatment. Method of measurement: Physical exam and score of CBSS (0,1,2,3). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFariba Goodarzi
Zahedan Medical University
Outcome results
None listed